Literature DB >> 15109522

Snake venom phospholipase A2s (Asp49 and Lys49) induce mechanical allodynia upon peri-sciatic administration: involvement of spinal cord glia, proinflammatory cytokines and nitric oxide.

Marucia Chacur1, Erin D Milligan, Evan M Sloan, Julie Wieseler-Frank, Ruth M Barrientos, David Martin, Stephen Poole, Brono Lomonte, Jose Maria Gutiérrez, Steven F Maier, Yara Cury, Linda R Watkins.   

Abstract

Snakebites constitute a serious public health problem in Central and South America, where species of the lancehead pit vipers (genus Bothrops) cause the majority of accidents. Bothrops envenomations are very painful, and this effect is not neutralized by antivenom treatment. Two variants of secretory phospholipases A2 (sPLA2), corresponding to Asp49 and Lys49 PLA2s, have been isolated from Bothrops asper venom. These sPLA2s induce hyperalgesia in rats following subcutaneous injection. However, venom in natural Bothrops bites is frequently delivered intramuscularly, thereby potentially reaching peripheral nerve bundles. Thus, the present series of experiments tested whether these sPLA2s could exert pain-enhancing effects following administration around healthy sciatic nerve. Both were found to produce mechanical allodynia ipsilateral to the injection site; no thermal hyperalgesia was observed. As no prior study has examined potential spinal mechanisms underlying sPLA2 actions, a series of anatomical and pharmacological studies were performed. These demonstrated that both sPLA2s produce activation of dorsal horn astrocytes and microglia that is more prominent ipsilateral to the site of injection. As proinflammatory cytokines and nitric oxide have each been previously implicated in spinally mediated pain facilitation, the effect of pharmacological blockade of these substances was tested. The results demonstrate that mechanical allodynia induced by both sPLA2s is blocked by interleukin-1 receptor antagonist, anti-rat interleukin-6 neutralizing antibody, the anti-inflammatory cytokine interleukin-10, and a nitric oxide synthesis inhibitor (L-NAME). As a variety of immune cells also produce and release sPLA2s during inflammatory states, the data may have general implications for the understanding of inflammatory pain.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15109522     DOI: 10.1016/j.pain.2003.12.023

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  22 in total

1.  Interleukin-6 mediates low-threshold mechanical allodynia induced by intrathecal HIV-1 envelope glycoprotein gp120.

Authors:  Diana K Schoeniger-Skinner; Annemarie Ledeboer; Matthew G Frank; Erin D Milligan; Stephen Poole; David Martin; Steven F Maier; Linda R Watkins
Journal:  Brain Behav Immun       Date:  2007-01-03       Impact factor: 7.217

Review 2.  "Listening" and "talking" to neurons: implications of immune activation for pain control and increasing the efficacy of opioids.

Authors:  Linda R Watkins; Mark R Hutchinson; Erin D Milligan; Steven F Maier
Journal:  Brain Res Rev       Date:  2007-07-13

3.  Intrathecal interleukin-10 gene therapy attenuates paclitaxel-induced mechanical allodynia and proinflammatory cytokine expression in dorsal root ganglia in rats.

Authors:  Annemarie Ledeboer; Brian M Jekich; Evan M Sloane; John H Mahoney; Stephen J Langer; Erin D Milligan; David Martin; Steven F Maier; Kirk W Johnson; Leslie A Leinwand; Raymond A Chavez; Linda R Watkins
Journal:  Brain Behav Immun       Date:  2006-12-15       Impact factor: 7.217

4.  High cerebrospinal fluid levels of interleukin-10 attained by AAV in dogs.

Authors:  J Pleticha; S A Malkmus; L F Heilmann; S L Veesart; R Rezek; Q Xu; T L Yaksh; A S Beutler
Journal:  Gene Ther       Date:  2014-10-30       Impact factor: 5.250

5.  miR-203 regulates nociceptive sensitization after incision by controlling phospholipase A2 activating protein expression.

Authors:  Yuan Sun; Xiang-Qi Li; Peyman Sahbaie; Xiao-You Shi; Wen-Wu Li; De-Yong Liang; J David Clark
Journal:  Anesthesiology       Date:  2012-09       Impact factor: 7.892

6.  PEGylation of interleukin-10 for the mitigation of enhanced pain states.

Authors:  Ryan G Soderquist; Erin D Milligan; Jacqueline A Harrison; Raymond A Chavez; Kirk W Johnson; Linda R Watkins; Melissa J Mahoney
Journal:  J Biomed Mater Res A       Date:  2010-06-01       Impact factor: 4.396

7.  Pre-treatment with Meloxicam Prevents the Spinal Inflammation and Oxidative Stress in DRG Neurons that Accompany Painful Cervical Radiculopathy.

Authors:  Sonia Kartha; Christine L Weisshaar; Blythe H Philips; Beth A Winkelstein
Journal:  Neuroscience       Date:  2018-08-04       Impact factor: 3.590

Review 8.  Spinal interleukin-10 therapy to treat peripheral neuropathic pain.

Authors:  Erin D Milligan; Kathryn R Penzkover; Ryan G Soderquist; Melissa J Mahoney
Journal:  Neuromodulation       Date:  2012-06-01

9.  Phospholipase A2 Inhibitor-Loaded Phospholipid Micelles Abolish Neuropathic Pain.

Authors:  Sonia Kartha; Lesan Yan; Meagan E Ita; Ahmad Amirshaghaghi; Lijun Luo; Yulong Wei; Andrew Tsourkas; Beth A Winkelstein; Zhiliang Cheng
Journal:  ACS Nano       Date:  2020-06-04       Impact factor: 15.881

10.  Neural mobilization reverses behavioral and cellular changes that characterize neuropathic pain in rats.

Authors:  Fabio M Santos; Joyce T Silva; Aline C Giardini; Priscila A Rocha; Arnold P P Achermann; Adilson S Alves; Luiz R G Britto; Marucia Chacur
Journal:  Mol Pain       Date:  2012-07-29       Impact factor: 3.395

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.